Letters to the Editor
Vol. 10 (2018): Review Articles, Original Articles, Scientific Letters, Case Reports
Cardiac toxicity associated with HCV direct antiviral agents
Heart in HCV DAAs therapy
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: October 29, 2018
1682
Views
950
Downloads
165
HTML
Authors
Downloads
Download data is not yet available.
Citations
1. Ucciferri C, Mancino P, Vignale F, Vecchiet J, Falasca K. Induction with ribavirin in a relapsing patient with chronic HCV hepatitis. Braz J Infect Dis 2012;16(3):297-9.https://doi.org/10.1016/S1413-8670(12)70328-82.
2. Maan R, van Tilborg M, Deterding K, Ramji A, van der Meer AJ, Wong F, Fung S, Sherman M, Manns MP, Cornberg M, Hansen BE, Wedemeyer H, Janssen HL, de Knegt RJ, Feld JJ. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. Clin GastroenterolHepatol.2016Dec;14(12):1821-1830.e6. doi:10.1016/j.cgh.2016.07.001.https://doi.org/10.1016/j.cgh.2016.07.0013.
3. Mancino P, Falasca K, Ucciferri C, Pizzigallo E, Vecchiet J. Use of hematopoietic growth factor in the management of hematological side effects associated to antiviral treatment for HCV hepatitis. Mediterr J HematolInfectDis2010;21):e2010003.https://doi.org/10.4084/mjhid.2010.0034.
4. Dahal,S.,Upadhyay,S.,Banjade,R.,Dhakal,P.,Khanal,N.,&Bhatt,V. R. (2017). Thrombocytopenia in patients with chronic hepatitis c virus infection. Mediterranean Journal of Hematology and Infectious Diseases, 2017, 9(1), e2017019.https://doi.org/10.4084/mjhid.2017.0195.
5. Back DJ, Burger DM. Interaction between amiodarone and sofosbuvir-based treatment for hepatitis C virus infection: potential mechanisms and lessons to be learned. Gastroenterology 2015;149(6):1315-7https://doi.org/10.1053/j.gastro.2015.09.031PMid:264163286.
6. Lagrutta A, Zeng H, Imredy J, Balasubramanian B, Dech S, Lis E, et al. Interaction between amiodarone and hepatitis-C virus nucleotide inhibitors in human induced pluripotent stem cell-derived cardiomyocytes and HEK-293 Cav1.2 over-expressing cells. Toxicol Appl Pharmacol 2016;308:66-76.https://doi.org/10.1016/j.taap.2016.08.006PMid:275207587.
7. Renet S, Chaumais MC, Antonini T, Zhao A, Thomas L, Savoure A, et al. Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge. Gastroenterology 2015;149(6):1378-80e1.8.
8. Ahmad T, Yin P, Saffitz J, Pockros PJ, Lalezari J, Shiffman M, et al. Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C. Hepatology 2015;62(2):409-16.https://doi.org/10.1002/hep.27488PMid:252511569.
9. Zahno A, Brecht K, Morand R, Maseneni S, Torok M, Lindinger PW, et al. The role of CYP3A4 in amiodarone-associated toxicity on HepG2 cells. Biochem Pharmacol 2011;81(3):432-41.https://doi.org/10.1016/j.bcp.2010.11.002PMid:21070748
.
2. Maan R, van Tilborg M, Deterding K, Ramji A, van der Meer AJ, Wong F, Fung S, Sherman M, Manns MP, Cornberg M, Hansen BE, Wedemeyer H, Janssen HL, de Knegt RJ, Feld JJ. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis. Clin GastroenterolHepatol.2016Dec;14(12):1821-1830.e6. doi:10.1016/j.cgh.2016.07.001.https://doi.org/10.1016/j.cgh.2016.07.0013.
3. Mancino P, Falasca K, Ucciferri C, Pizzigallo E, Vecchiet J. Use of hematopoietic growth factor in the management of hematological side effects associated to antiviral treatment for HCV hepatitis. Mediterr J HematolInfectDis2010;21):e2010003.https://doi.org/10.4084/mjhid.2010.0034.
4. Dahal,S.,Upadhyay,S.,Banjade,R.,Dhakal,P.,Khanal,N.,&Bhatt,V. R. (2017). Thrombocytopenia in patients with chronic hepatitis c virus infection. Mediterranean Journal of Hematology and Infectious Diseases, 2017, 9(1), e2017019.https://doi.org/10.4084/mjhid.2017.0195.
5. Back DJ, Burger DM. Interaction between amiodarone and sofosbuvir-based treatment for hepatitis C virus infection: potential mechanisms and lessons to be learned. Gastroenterology 2015;149(6):1315-7https://doi.org/10.1053/j.gastro.2015.09.031PMid:264163286.
6. Lagrutta A, Zeng H, Imredy J, Balasubramanian B, Dech S, Lis E, et al. Interaction between amiodarone and hepatitis-C virus nucleotide inhibitors in human induced pluripotent stem cell-derived cardiomyocytes and HEK-293 Cav1.2 over-expressing cells. Toxicol Appl Pharmacol 2016;308:66-76.https://doi.org/10.1016/j.taap.2016.08.006PMid:275207587.
7. Renet S, Chaumais MC, Antonini T, Zhao A, Thomas L, Savoure A, et al. Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge. Gastroenterology 2015;149(6):1378-80e1.8.
8. Ahmad T, Yin P, Saffitz J, Pockros PJ, Lalezari J, Shiffman M, et al. Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C. Hepatology 2015;62(2):409-16.https://doi.org/10.1002/hep.27488PMid:252511569.
9. Zahno A, Brecht K, Morand R, Maseneni S, Torok M, Lindinger PW, et al. The role of CYP3A4 in amiodarone-associated toxicity on HepG2 cells. Biochem Pharmacol 2011;81(3):432-41.https://doi.org/10.1016/j.bcp.2010.11.002PMid:21070748
.
How to Cite
“Cardiac toxicity associated with HCV direct antiviral agents: Heart in HCV DAAs therapy” (2018) Mediterranean Journal of Hematology and Infectious Diseases, 10(1), p. e2018069. doi:10.4084/mjhid.2018.069.
